Olaparib and talazoparib currently are the only PARPi approved for patients with hormone receptor-positive/HER2-negative advanced breast cancer and a BRCA1 or BRCA2 mutation detected by germline sequencing. The gene discussed is BRCA1; the disease is breast cancer.